{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T14:49:29Z","timestamp":1792162169019,"version":"4.4.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"The Science and Technology Program of Lishui: Lishui Public Welfare Technology Application Research Plan Project","award":["2023GYX68"],"award-info":[{"award-number":["2023GYX68"]}]},{"name":"The Science and Technology Program of Lishui: Lishui Public Welfare Technology Application Research Plan Project","award":["2024GYX33"],"award-info":[{"award-number":["2024GYX33"]}]},{"name":"Zhejiang Medicine and Health Technology Plan","award":["2024KY1844"],"award-info":[{"award-number":["2024KY1844"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-12927-z","type":"journal-article","created":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T14:22:35Z","timestamp":1792160555000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["NEK2 promotes trastuzumab resistance in gastric cancer through WTAP\/YTHDF1-dependent m6A regulation of FN1"],"prefix":"10.1007","volume":"53","author":[{"given":"Zengchao","family":"Shen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongtao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junwei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minyue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,16]]},"reference":[{"issue":"3","key":"12927_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I et al (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74(3):229\u2013263","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"12927_CR2","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41420-025-02825-x","volume":"11","author":"L Zhou","year":"2025","unstructured":"Zhou L, Wei Y, Lin K, Lu Y (2025) L-Tetrahydropalmatine synergizes cytotoxic CD8\u2009+\u2009T mediated antitumor and ferroptosis in gastric cancer. Cell Death Discov 11(1):541","journal-title":"Cell Death Discov"},{"issue":"1","key":"12927_CR3","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/s41420-025-02815-z","volume":"11","author":"Y Hu","year":"2025","unstructured":"Hu Y, Shen F, Zhang H, Long Z, Zhao X, Wen J et al (2025) Single-cell and spatial dissection of necroptosis spatiotemporal evolution driving lymph node metastasis in gastric cancer. Cell Death Discov 11(1):535","journal-title":"Cell Death Discov"},{"issue":"1","key":"12927_CR4","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/s41420-025-02811-3","volume":"11","author":"Y Li","year":"2025","unstructured":"Li Y, Liu W, Zheng L, Zhu G, Qian X, Zeng R et al (2025) Hypomethylation-mediated upregulation of PHOX1 promotes gastric cancer progression via transactivation of NGFR. Cell Death Discov 11(1):548","journal-title":"Cell Death Discov"},{"key":"12927_CR5","doi-asserted-by":"crossref","unstructured":"Laurenziello P, Luongo M, Lospinoso Severini F, Calice G, Bartolo O, Falco G et al (2026) Salinomycin as a death switch: how gastric cancer cells choose their demise. Cell Death Discov 12(1):171","DOI":"10.1038\/s41420-026-03058-2"},{"issue":"1","key":"12927_CR6","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/s41420-025-02771-8","volume":"11","author":"Y Zhu","year":"2025","unstructured":"Zhu Y, Ma Y, Li W, Pan Y, Wang Y, Ye Q et al (2025) Targeting GPX2 to disrupt lipid homeostasis and enhance cisplatin sensitivity in diffuse gastric cancer. Cell Death Discov 11(1):491","journal-title":"Cell Death Discov"},{"issue":"1","key":"12927_CR7","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/cac2.12516","volume":"44","author":"F-H Wang","year":"2023","unstructured":"Wang F-H, Zhang X-T, Tang L, Wu Q, Cai M-Y, Li Y-F et al (2023) The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023. Cancer Commun (Lond) 44(1):127\u2013172","journal-title":"Cancer Commun (Lond)"},{"issue":"1","key":"12927_CR8","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.molmed.2024.07.013","volume":"31","author":"J Xia","year":"2024","unstructured":"Xia J, Zhao H, Edmondson JL, Koss B, Zhan F (2024) Role of NEK2 in tumorigenesis and tumor progression. Trends Mol Med 31(1):79\u201393","journal-title":"Trends Mol Med"},{"issue":"11","key":"12927_CR9","first-page":"2364","volume":"9","author":"Y Li","year":"2019","unstructured":"Li Y, Chen L, Feng L, Zhu M, Shen Q, Fang Y et al (2019) NEK2 promotes proliferation, migration and tumor growth of gastric cancer cells via regulating KDM5B\/H3K4me3. Am J Cancer Res 9(11):2364\u20132378","journal-title":"Am J Cancer Res"},{"issue":"23","key":"12927_CR10","doi-asserted-by":"publisher","first-page":"2898","DOI":"10.3748\/wjg.v25.i23.2898","volume":"25","author":"W-D Fan","year":"2019","unstructured":"Fan W-D, Chen T, Liu P-J (2019) NIMA related kinase 2 promotes gastric cancer cell proliferation via ERK\/MAPK signaling. World J Gastroenterol 25(23):2898\u20132910","journal-title":"World J Gastroenterol"},{"issue":"1","key":"12927_CR11","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s13105-020-00776-8","volume":"77","author":"H Wan","year":"2020","unstructured":"Wan H, Xu L, Zhang H, Wu F, Zeng W, Li T (2020) High expression of NEK2 promotes gastric cancer progression via activating AKT signaling. J Physiol Biochem 77(1):25\u201334","journal-title":"J Physiol Biochem"},{"key":"12927_CR12","doi-asserted-by":"publisher","first-page":"109737","DOI":"10.1016\/j.intimp.2023.109737","volume":"116","author":"Z Wu","year":"2023","unstructured":"Wu Z, Zheng J, Zhang H, Shen N, Luo X, Shen C et al (2023) Molecular characteristics, oncogenic roles, and relevant immune and pharmacogenomic features of NEK2 in gastric cancer. Int Immunopharmacol 116:109737","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"12927_CR13","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s11010-024-04960-y","volume":"480","author":"J Wu","year":"2024","unstructured":"Wu J, Luo D, Tou L, Xu H, Jiang C, Wu D et al (2024) NEK2 affects the ferroptosis sensitivity of gastric cancer cells by regulating the expression of HMOX1 through Keap1\/Nrf2. Mol Cell Biochem 480(1):425\u2013437","journal-title":"Mol Cell Biochem"},{"issue":"1","key":"12927_CR14","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12935-025-03644-x","volume":"25","author":"J Haiye","year":"2025","unstructured":"Haiye J, Xiangzhu W, Yunfei Z, Shumin G, Chang N, Yaohui J et al (2025) Overexpressed NEK2 contributes to progression and cisplatin resistance through activating the Wnt\/\u03b2-catenin signaling pathway in cervical cancer. Cancer Cell Int 25(1):45","journal-title":"Cancer Cell Int"},{"issue":"1","key":"12927_CR15","doi-asserted-by":"publisher","first-page":"4536","DOI":"10.1038\/s41467-021-24769-3","volume":"12","author":"X Zhang","year":"2021","unstructured":"Zhang X, Huang X, Xu J, Li E, Lao M, Tang T et al (2021) NEK2 inhibition triggers anti-pancreatic cancer immunity by targeting PD-L1. Nat Commun 12(1):4536","journal-title":"Nat Commun"},{"key":"12927_CR16","doi-asserted-by":"crossref","unstructured":"Zhu Y, Jian X, Chen S, An G, Jiang D, Yang Q et al (2023) Targeting gut microbial nitrogen recycling and cellular uptake of ammonium to improve bortezomib resistance in multiple myeloma. Cell Metab 36(1):159-175.e8","DOI":"10.1016\/j.cmet.2023.11.019"},{"issue":"8","key":"12927_CR17","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1158\/2159-8290.CD-24-0002","volume":"14","author":"J Prakash","year":"2024","unstructured":"Prakash J, Shaked Y (2024) The Interplay between Extracellular Matrix Remodeling and Cancer Therapeutics. Cancer Discov 14(8):1375\u20131388","journal-title":"Cancer Discov"},{"issue":"1","key":"12927_CR18","doi-asserted-by":"publisher","first-page":"5723","DOI":"10.1038\/s41467-022-33282-0","volume":"13","author":"Y Li","year":"2022","unstructured":"Li Y, Xu C, Wang B, Xu F, Ma F, Qu Y et al (2022) Proteomic characterization of gastric cancer response to chemotherapy and targeted therapy reveals new therapeutic strategies. Nat Commun 13(1):5723","journal-title":"Nat Commun"},{"issue":"1","key":"12927_CR19","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40164-022-00260-7","volume":"11","author":"Z Qin","year":"2022","unstructured":"Qin Z, Zhou C (2022) HOXA13 promotes gastric cancer progression partially via the FN1-mediated FAK\/Src axis. Exp Hematol Oncol 11(1):7","journal-title":"Exp Hematol Oncol"},{"key":"12927_CR20","doi-asserted-by":"publisher","first-page":"154179","DOI":"10.1016\/j.prp.2022.154179","volume":"239","author":"J Li","year":"2022","unstructured":"Li J, Chen C, Chen B, Guo T (2022) High FN1 expression correlates with gastric cancer progression. Pathol Res Pract 239:154179","journal-title":"Pathol Res Pract"},{"issue":"1","key":"12927_CR21","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s13062-024-00481-2","volume":"19","author":"Y Lin","year":"2024","unstructured":"Lin Y, Li Y, Chen X, Jin X, Jiang M, Xiao H et al (2024) YY1 mediated DCUN1D5 transcriptional activation promotes triple-negative breast cancer progression by targeting FN1\/PI3K\/AKT pathway. Biol Direct 19(1):42","journal-title":"Biol Direct"},{"key":"12927_CR22","doi-asserted-by":"publisher","first-page":"102877","DOI":"10.1016\/j.mtbio.2026.102877","volume":"37","author":"M Tian","year":"2026","unstructured":"Tian M, Meng X, Song W, Wu Z, Liu Y, Dong X et al (2026) Targeting FN1 to overcome gemcitabine resistance in gallbladder cancer: Mechanistic insights and an iRGD-modified PEG-PLGA nanoparticle delivery strategy. Mater Today Bio 37:102877","journal-title":"Mater Today Bio"},{"issue":"18","key":"12927_CR23","doi-asserted-by":"publisher","first-page":"8317","DOI":"10.18632\/oncotarget.2135","volume":"5","author":"G Li","year":"2014","unstructured":"Li G, Zhao L, Li W, Fan K, Qian W, Hou S et al (2014) Feedback activation of STAT3 mediates trastuzumab resistance via upregulation of MUC1 and MUC4 expression. Oncotarget 5(18):8317\u20138329","journal-title":"Oncotarget"},{"key":"12927_CR24","doi-asserted-by":"publisher","first-page":"11634","DOI":"10.1038\/srep11634","volume":"5","author":"Q Zuo","year":"2015","unstructured":"Zuo Q, Liu J, Zhang J, Wu M, Guo L, Liao W (2015) Development of trastuzumab-resistant human gastric carcinoma cell lines and mechanisms of drug resistance. Sci Rep 5:11634","journal-title":"Sci Rep"},{"key":"12927_CR25","doi-asserted-by":"publisher","first-page":"102186","DOI":"10.1016\/j.tranon.2024.102186","volume":"51","author":"H Qin","year":"2024","unstructured":"Qin H, Yuan M, Yuan Y, Xia F, Yang Y (2024) NEK2 promotes colorectal cancer progression by activating the TGF-\u03b2\/Smad2 signaling pathway. Transl Oncol 51:102186","journal-title":"Transl Oncol"},{"issue":"2","key":"12927_CR26","doi-asserted-by":"publisher","first-page":"405","DOI":"10.3892\/ijo.2017.3837","volume":"50","author":"G Li","year":"2017","unstructured":"Li G, Zhong Y, Shen Q, Zhou Y, Deng X, Li C et al (2017) NEK2 serves as a prognostic biomarker for hepatocellular carcinoma. Int J Oncol 50(2):405\u2013413","journal-title":"Int J Oncol"},{"issue":"9","key":"12927_CR27","doi-asserted-by":"publisher","first-page":"e69","DOI":"10.1038\/oncsis.2013.34","volume":"2","author":"TK Das","year":"2013","unstructured":"Das TK, Dana D, Paroly SS, Perumal SK, Singh S, Jhun H et al (2013) Centrosomal kinase Nek2 cooperates with oncogenic pathways to promote metastasis. Oncogenesis 2(9):e69","journal-title":"Oncogenesis"},{"key":"12927_CR28","doi-asserted-by":"publisher","first-page":"117287","DOI":"10.1016\/j.ejmech.2025.117287","volume":"286","author":"Y Jiang","year":"2025","unstructured":"Jiang Y, Wang Y, Su F, Hou Y, Liao W, Li B et al (2025) Insights into NEK2 inhibitors as antitumor agents: From mechanisms to potential therapeutics. Eur J Med Chem 286:117287","journal-title":"Eur J Med Chem"},{"issue":"7","key":"12927_CR29","doi-asserted-by":"publisher","first-page":"2877","DOI":"10.1172\/JCI98765","volume":"128","author":"R Franqui-Machin","year":"2018","unstructured":"Franqui-Machin R, Hao M, Bai H, Gu Z, Zhan X, Habelhah H et al (2018) Destabilizing NEK2 overcomes resistance to proteasome inhibition in multiple myeloma. J Clin Invest 128(7):2877\u20132893","journal-title":"J Clin Invest"},{"issue":"2","key":"12927_CR30","doi-asserted-by":"publisher","first-page":"108196","DOI":"10.1016\/j.jbc.2025.108196","volume":"301","author":"JR Bobbitt","year":"2025","unstructured":"Bobbitt JR, Cuellar-Vite L, Weber-Bonk KL, Yancey MR, Majmudar PR, Keri RA (2025) Targeting the mitotic kinase NEK2 enhances CDK4\/6 inhibitor efficacy by potentiating genome instability. J Biol Chem 301(2):108196","journal-title":"J Biol Chem"},{"issue":"1","key":"12927_CR31","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1186\/s13046-019-1311-z","volume":"38","author":"L Deng","year":"2019","unstructured":"Deng L, Sun J, Chen X, Liu L, Wu D (2019) Nek2 augments sorafenib resistance by regulating the ubiquitination and localization of \u03b2-catenin in hepatocellular carcinoma. J Exp Clin Cancer Res 38(1):316","journal-title":"J Exp Clin Cancer Res"},{"key":"12927_CR32","doi-asserted-by":"crossref","unstructured":"Millap\u00e1n T, Guti\u00e9rrez \u00c1, Rosas K, Buchegger K, Ili CG, Brebi P (2024) In Silico Insights Reveal Fibronectin 1 as a Theranostic Marker in Gastric Cancer. Int J Mol Sci 25(20):11113","DOI":"10.3390\/ijms252011113"},{"issue":"3","key":"12927_CR33","doi-asserted-by":"publisher","first-page":"306","DOI":"10.21147\/j.issn.1000-9604.2024.03.07","volume":"36","author":"Z Li","year":"2024","unstructured":"Li Z, Zhao H, Hu H, Shang H, Ren Y, Qiu W et al (2024) Mechanisms of resistance to trastuzumab in HER2-positive gastric cancer. Chin J Cancer Res 36(3):306\u2013321","journal-title":"Chin J Cancer Res"},{"issue":"1","key":"12927_CR34","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s10495-025-02218-6","volume":"31","author":"X Zhang","year":"2026","unstructured":"Zhang X, Liu Y, Liu X, Tan J, Yuan L, Wu W et al (2026) Downregulation of NFIA facilitates glycolysis, histone lactylation, and activation of the FN1-integrin \u03b15\u03b21 pathway in pancreatic cancer. Apoptosis 31(1):4","journal-title":"Apoptosis"},{"issue":"1","key":"12927_CR35","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/s41392-020-00453-8","volume":"6","author":"Q Li","year":"2021","unstructured":"Li Q, Ni Y, Zhang L, Jiang R, Xu J, Yang H et al (2021) HIF-1\u03b1-induced expression of m6A reader YTHDF1 drives hypoxia-induced autophagy and malignancy of hepatocellular carcinoma by promoting ATG2A and ATG14 translation. Signal Transduct Target Ther 6(1):76","journal-title":"Signal Transduct Target Ther"},{"issue":"6","key":"12927_CR36","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1038\/s41375-023-01904-1","volume":"37","author":"Y-L Shao","year":"2023","unstructured":"Shao Y-L, Li Y-Q, Li M-Y, Wang L-L, Zhou H-S, Liu D-H et al (2023) HIF1\u03b1-mediated transactivation of WTAP promotes AML cell proliferation via m6A-dependent stabilization of KDM4B mRNA. Leukemia 37(6):1254\u20131267","journal-title":"Leukemia"},{"issue":"8","key":"12927_CR37","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1016\/j.bbagen.2017.05.009","volume":"1861","author":"S Aghazadeh","year":"2017","unstructured":"Aghazadeh S, Yazdanparast R (2017) Activation of STAT3\/HIF-1\u03b1\/Hes-1 axis promotes trastuzumab resistance in HER2-overexpressing breast cancer cells via down-regulation of PTEN. Biochim Biophys Acta Gen Subj 1861(8):1970\u20131980","journal-title":"Biochim Biophys Acta Gen Subj"},{"issue":"11","key":"12927_CR38","doi-asserted-by":"publisher","first-page":"e52101","DOI":"10.15252\/embr.202052101","volume":"22","author":"Y Ge","year":"2021","unstructured":"Ge Y, Ling T, Wang Y, Jia X, Xie X, Chen R et al (2021) Degradation of WTAP blocks antiviral responses by reducing the m6 A levels of IRF3 and IFNAR1 mRNA. EMBO Rep 22(11):e52101","journal-title":"EMBO Rep"},{"issue":"6","key":"12927_CR39","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1111\/cas.16136","volume":"115","author":"Q-Z Liu","year":"2024","unstructured":"Liu Q-Z, Zhang N, Chen J-Y, Zhou M-J, Zhou D-H, Chen Z et al (2024) WTAP-induced N6-methyladenosine of PD-L1 blocked T-cell-mediated antitumor activity under hypoxia in colorectal cancer. Cancer Sci 115(6):1749\u20131762","journal-title":"Cancer Sci"},{"issue":"4","key":"12927_CR40","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1093\/neuonc\/noae268","volume":"27","author":"J Qiu","year":"2025","unstructured":"Qiu J, Zhao R, Ma C, Wang Q, Li B, Qi Y et al (2025) O-GlcNAcylation stabilized WTAP promotes GBM malignant progression in an N6-methyladenosine-dependent manner. Neuro Oncol 27(4):900\u2013915","journal-title":"Neuro Oncol"},{"issue":"4","key":"12927_CR41","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1002\/1878-0261.12641","volume":"14","author":"J Xia","year":"2020","unstructured":"Xia J, He Y, Meng B, Chen S, Zhang J, Wu X et al (2020) NEK2 induces autophagy-mediated bortezomib resistance by stabilizing Beclin-1 in multiple myeloma. Mol Oncol 14(4):763\u2013778","journal-title":"Mol Oncol"},{"key":"12927_CR42","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.jare.2024.06.019","volume":"71","author":"Q Chen","year":"2024","unstructured":"Chen Q, Ao L, Zhao Q, Tang L, Xiong Y, Yuan Y et al (2024) WTAP\/YTHDF1-mediated m6A modification amplifies IFN-\u03b3-induced immunosuppressive properties of human MSCs. J Adv Res 71:441\u2013455","journal-title":"J Adv Res"},{"key":"12927_CR43","doi-asserted-by":"publisher","first-page":"111075","DOI":"10.1016\/j.biopha.2020.111075","volume":"133","author":"H Yu","year":"2020","unstructured":"Yu H, Zhao K, Zeng H, Li Z, Chen K, Zhang Z et al (2020) N6-methyladenosine (m6A) methyltransferase WTAP accelerates the Warburg effect of gastric cancer through regulating HK2 stability. Biomed Pharmacother 133:111075","journal-title":"Biomed Pharmacother"},{"issue":"8","key":"12927_CR44","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1158\/0008-5472.CAN-21-1820","volume":"82","author":"J Wang","year":"2022","unstructured":"Wang J, Huang Q, Hu X, Zhang S, Jiang Y, Yao G et al (2022) Disrupting Circadian Rhythm via the PER1-HK2 Axis Reverses Trastuzumab Resistance in Gastric Cancer. Cancer Res 82(8):1503\u20131517","journal-title":"Cancer Res"},{"issue":"1","key":"12927_CR45","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1186\/s12935-021-02312-0","volume":"21","author":"Q Chen","year":"2021","unstructured":"Chen Q, Li L, Liu X, Feng Q, Zhang Y, Zheng P et al (2021) Hexokinases 2 promoted cell motility and distant metastasis by elevating fibronectin through Akt1\/p-Akt1 in cervical cancer cells. Cancer Cell Int 21(1):600","journal-title":"Cancer Cell Int"},{"issue":"10","key":"12927_CR46","doi-asserted-by":"publisher","first-page":"2651","DOI":"10.1158\/0008-5472.CAN-20-0066","volume":"81","author":"J Pi","year":"2020","unstructured":"Pi J, Wang W, Ji M, Wang X, Wei X, Jin J et al (2020) YTHDF1 Promotes Gastric Carcinogenesis by Controlling Translation of FZD7. Cancer Res 81(10):2651\u20132665","journal-title":"Cancer Res"},{"issue":"1","key":"12927_CR47","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1186\/s12885-023-11447-4","volume":"23","author":"Y Kim","year":"2023","unstructured":"Kim Y, Bae YJ, Kim J-H, Kim H, Shin S-J, Jung DH et al (2023) Wnt\/\u03b2-catenin pathway is a key signaling pathway to trastuzumab resistance in gastric cancer cells. BMC Cancer 23(1):922","journal-title":"BMC Cancer"},{"issue":"12","key":"12927_CR48","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.1002\/ijc.30408","volume":"139","author":"F Pietrantonio","year":"2016","unstructured":"Pietrantonio F, Caporale M, Morano F, Scartozzi M, Gloghini A, De Vita F et al (2016) HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research. Int J Cancer 139(12):2859\u20132864","journal-title":"Int J Cancer"},{"issue":"4","key":"12927_CR49","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s10585-022-10169-4","volume":"39","author":"F Zhao","year":"2022","unstructured":"Zhao F, Ge F, Xie M, Li Z, Zang C, Kong L et al (2022) FTO mediated ERBB2 demethylation promotes tumor progression in esophageal squamous cell carcinoma cells. Clin Exp Metastasis 39(4):623\u2013639","journal-title":"Clin Exp Metastasis"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12927-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-12927-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12927-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T14:22:37Z","timestamp":1792160557000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-12927-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,16]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["12927"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-12927-z","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,16]]},"assertion":[{"value":"30 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent to Publish","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1738"}}